Dibutyltin(IV) complexes containing arylazobenzoate ligands: Chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes

Investigational New Drugs

Volumn 29, Issue 2, 2011, Pages 285-299

  Basu Baul, Tushar S ^a   Paul, Anup ^a   Pellerito, Lorenzo ^b   Scopelliti, Michelangelo ^b   Singh, Palwinder ^c   Verma, Pooja ^c   Duthie, Andrew ^d   De Vos, Dick ^e   Tiekink, Edward R T ^f  

^a NORTH EASTERN HILL UNIVERSITY   (India)

^b UNIVERSITY OF PALERMO   (Italy)

^c GURU NANAK DEV UNIVERSITY   (India)

^d DEAKIN UNIVERSITY   (Australia)

^e TEVA Pharmachemie   (Netherlands)

^f UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Anti cancer drugs; Arylazobenzoate; Cell lines; Dibutyltin(IV) compounds; Docking studies; Spectroscopy

Indexed keywords

2 [(5 TERT BUTYL 2 HYDROXYPHENYL)DIAZENYL]BENZOATE; 4 [(5 TERT BUTYL 2 HYDROXYPHENYL)DIAZENYL]BENZOATE; 4 [(5 TERT BUTYL 2 METHYLPHENYL)DIAZENYL]BENZOATE; ARYLAZOBENZOATE; BENZOIC ACID DERIVATIVE; CISPLATIN; DIBUTYLTIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; PHOSPHORYLASE; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TIN; UNCLASSIFIED DRUG; DI-N-BUTYLTIN; ENZYME; LIGAND; ORGANOTIN COMPOUND;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN A 498; CELL STRAIN EVSA T; CELL STRAIN H226; CELL STRAIN IGROV; CELL STRAIN M19; CELL STRAIN MCF 7; CELL STRAIN MEL; CELL STRAIN WIDR; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; KIDNEY CANCER; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MELANOMA CELL; MOLECULAR DOCKING; MOSSBAUER SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL; BINDING SITE; CELL DEATH; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG EFFECT; DRUG SCREENING; HYDROGEN BOND; METABOLISM; QUANTUM THEORY; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CELL DEATH; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYMES; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; ORGANOTIN COMPOUNDS; QUANTUM THEORY; RIBONUCLEOTIDE REDUCTASES; THYMIDYLATE SYNTHASE;

EID: 79957555617     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9360-3     Document Type: Article

References (70)

1. Abu-Surrah AS, Kettunen M (2006) Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Curr Med Chem 13:1337-1357
2. Barnes KR, Lippard SJ (2004) Metal complexes in tumor diagnosis and as anticancer agents. Met Ions Biol Syst 42:143-177
3. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM (2007) Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 7:3-18 (Pubitemid 46062402)
4. Yang P, Guo M (1999) Interactions of organometallic anticancer agents with nucleotides and DNA. Coord Chem Rev 185- 186:189-211
5. Reedijk J (2003) New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA 100:3611-3616 (Pubitemid 36422584)
6. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer. Nat Rev Drug Discov 4:307-320
7. Sigel A, Sigel H (2004) Metal ions in biological systems. Marcel Dekkar, New York
8. Jakupec M, Keppler BK (2004) In: Sigel A, Sigel H (eds) Metal ions in biological systems. Marcel Dekker, New York
9. Alessio E, Mestroni G, Bergamo A, Sava G (2004) Ruthenium antimetastatic agents. Curr Top Med Chem 4:1525-1535 (Pubitemid 39662663)
10. Sigel A, Sigel H (2005) Metal ions in biological systems. Wiley, New York
11. Gielen M, Tiekink ERT (eds) (2005) Metallotherapeutic drug and metal-based diagnostic agents. Wiley, Chichester, England
12. Ang WH, Dyson PJ (2006) Classical and non-classical rutheniumbased anticancer drugs: towards targeted chemotherapy (review). Eur J Inorg Chem 4003-4018
13. Bruijnincx PCA, Sadler PJ (2008) New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 12:197-206
14. Tiekink ERT (2008) Anti-cancer potential of gold complexes. Inflammopharmacol 16:138-142
15. Hadjikakou SK, Hadjiliadis N (2009) Antiproliferative and antitumor activity of organotin compounds. Coord Chem Rev 253:235-249
16. Tiekink ERT (1994) The rich diversity in tin carboxylate structures. Trends Organomet Chem 1:71-116
17. Tiekink ERT (1991) Structural chemistry of organotin carboxylates: a review of the crystallographic literature. Appl Organomet Chem 5:1-21
18. Chandrasekhar V, Nagendran S, Baskar V (2002) Organotin assemblies containing Sn-O bonds. Coord Chem Rev 235:1-52
19. Buntine MA, Hall VJ, Kosovel FJ, Tiekink ERT (1998) Influence of crystal packing on molecular geometry: a crystallographic and theoretical investigation of selected diorganotin systems. J Phy Chem A 102:2472-2482 (Pubitemid 128635979)
20. 117Sn NMR data with X-ray diffraction structural data of triorganotin 2-[(E)-2-(2-Hydroxy-5-methylphenyl)- 1-diazenyl]benzoates. Organometallics 17:5758-5766
21. Dakternieks D, Duthie A, Smyth DR, Stapleton CPD, Tiekink ERT (2003) Steric control over molecular structure and supramolecular association exerted by tin- and ligand-bound groups in diorganotin carboxylates. Organometallics 22:4599-4603
22. Prabusankar G, Murugavel R (2004) Hexameric organotincarboxylates with cyclic and drum structures. Organometallics 23:5644-5647
23. Gielen M, Tiekink ERT (eds) (2005) Metallotherapeutic drug and metal-based diagnostic agents: 50Sn Tin compounds and their therapeutic potential. Wiley, Chichester, pp 421-439 (and references therein)
24. Basu Baul TS, Basu S, de Vos D, Linden A (2009) Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies. Invest New Drugs 27:419-431
25. Basu Baul TS, Masharing C, Ruisi G, Jirásko R, Holèapek M, de Vos D, Wolstenholme D, Linden A (2007) Self-assembly of extended Schiff base amino acetate skeletons, 2-{[(2Z)-(3- hydroxy-1-methyl-2-butenylidene)]amino} phenylpropionate and 2-{[(E)-1-(2-hydroxyaryl)alkylidene]amino}phenylpropionate skeletons incorporating organotin(IV) moieties: synthesis, spectroscopic characterization, crystal structures, and in vitro cytotoxic activity. J Organomet Chem 692:4849-4862 (Pubitemid 47440157)
26. Basu Baul TS, Paul A, Pellerito L, Scopelliti M, Singh P, Verma P, de Vos D (2009) Triphenyltin(IV) 2-[(E)-2-(aryl)-1-diazenyl] benzoates as anticancer drugs: synthesis, structural characterization, in vitro cytotoxicity and study of its influence towards the mechanistic role of some key enzymes. Invest New Drugs. doi:10.1007-s10637-009-9293-x
27. Corral E, Hotze ACG, den Dulk H, Leczkowska A, Rodger A, Hannon MJ, Reedijk J (2009) Ruthenium polypyridyl complexes and their modes of interaction with DNA: is there a correlation between these interactions and the antitumor activity of the compounds? J Biol Inorg Chem 14:439-448
28. Basu Baul TS, Rynjah W, Willem R, Biesemans M, Verbruggen I, Holèapek M, de Vos D, Linden A (2004) Dibutyltin(IV) complexes of the 5-[(E)-2-(Aryl)-1-diazenyl]-2-hydroxybenzoic acid ligand: an investigation of structures by X-ray diffraction, solution and solid state tin NMR, electrospray ionisation MS and assessment of in vitro cytotoxicity. J Organomet Chem 689:4691-4701 (Pubitemid 40090418)
29. Basu Baul TS, Rynjah W, Rivarola E, Lyèka A, Holèapek M, Jirásko R, de Vos D, Butcher RJ, Linden A (2006) Synthesis and characterization of bis[dicarboxylatotetraorganodistannoxane] units involving 5-[(E)-2-(aryl)-1-diazenyl]-2-hydroxybenzoic acids: an investigation of structures by X-ray diffraction, NMR, electrospray ionization MS and assessment of in vitro cytotoxicity. J Organomet Chem 691:4850-4862 (Pubitemid 44754748)
30. Basu Baul TS, Paul A, Arman HD, Tiekink ERT (2008) 2-[(E)-(5- tert-Butyl-2-hydroxyphenyl)diazenyl]benzoic acid. Acta Crystallogr Sect. E 64:o2125
31. Boyd MR (1989) Status of the NCI preclinical antitumor drug discovery screen. Principles and practice of oncology, vol 3. Lippincott, Philadelphia, pp 1-12
32. Keepers YP, Pizao PR, Peters GJ, Ark-Otte JV, Winograd B, Pinedo HM (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27:897-900
33. Higashi T (1995) ABSCOR. Rigaku Corporation, Tokyo, Japan
34. Beurskens PT, Admiraal G, Beurskens G, Bosman WP, García- Granda S, Smits JMM, Smykalla C (1992) The DIRDIF program system, technical report of the Crystallography Laboratory. University of Nijmegen, The Netherlands
35. Sheldrick GM (2008) A short history of SHELX. Acta Crystallogr A A64:112-122
36. Johnson CK (1976) ORTEP II, Report ORNL-5136. Oak Ridge National Laboratory, Oak Ridge, TN
37. Brandenburg K (2006) DIAMOND. Crystal impact GbR, Bonn, Germany
38. Stewart JJP (1989) Optimization of parameters for semiempirical methods: I. Method. J Comput Chem 10:209-220
39. Stewart JJP (1989) Optimization of parameters for semiempirical methods: II. Applications. J Comput Chem 10:221-264
40. Stewart JJP (1991) Optimization of parameters for semiempirical methods: III. Extension of PM3 to Be, Mg, Zn, Ga, Ge, As, Se, Cd, In, Sn, Sb, Te, Hg, Tl, Pb, and Bi. J Comput Chem 12:320-341
41. Stewart JJP (2004) Optimization of parameters for semiempirical methods IV. Extension of MNDO, AM1, and PM3 to more main group elements. J Mol Model 10:155-164 (Pubitemid 38678941)
42. Stewart JJP (2007) Optimization of parameters for semiempirical methods V: Modification of NDDO approximations and application to 70 elements. J Mol Model 13:1173-1213 (Pubitemid 47629446)
43. VandeVondele J, Krack M, Mohamed F, Parrinello M, Chassaing T, Hutter J (2005) Quickstep: fast and accurate density functional calculations using a mixed Gaussian and plane waves approach. Comp Phys Comm 167:103-128 (Pubitemid 40391124)
44. ArgusLab 4.0.1: Thompson MA, Planaria Software LLC, Seattle, WA, http://www.argusLab.com
45. Protein Data Bank, http://www.rcsb.org/pdb/
46. Wang R, Lai L, Wang S (2002) Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 16:11-26 (Pubitemid 34855041)
47. Basu Baul TS, Pyke SM, SarmaKK, Tiekink ERT (1996) Crystal and molecular structure of aquatriphenyltin 2-(3-formyl-4-hydroxyphenylazo) benzoate. Main Group met. Chem. 19:807-814
48. Basu Baul TS, Dhar S, Pyke SM, Tiekink ERT, Rivarola E, Butcher R, Smith FE (2001) Synthesis and characterization of triorganotin (IV) complexes of 5-[(E)-2-(aryl)-1-diazenyl]-2-hydroxybenzoic acids. Crystal and molecular structures of a series of triphenyltin 5-[(E)-2-(aryl)-1-diazenyl]-2- hydroxybenzoates (aryl=phenyl, 2- methylphenyl, 3-methylphenyl and 4-methoxyphenyl). J Organomet Chem 633:7-17 (Pubitemid 33618302)
49. Basu Baul TS, Dhar S, Rivarola E, Smith FE, Butcher R, Song X, McCain M, Eng G (2003) Synthesis and characterization of some dibutylbis{5-[(E)-2-(aryl)- 1-diazenyl]-2-hydroxybenzoato}tin(IV) compounds. Toxicity studies of di- and tri-organotin complexes on the second instar of Aedes aegypti mosquito larvae. Appl Organomet Chem 17:261-267
50. Basu Baul TS, Rynjah W, Rivarola E, Pettinary C, Linden A (2005) Synthesis and characterization of the first diorganotin(IV) complexes containing mixed arylazobenzoic acids and having skew trapezoidal bipyramidal geometry. J Organomet Chem 690:1413-1421 (Pubitemid 40312854)
51. 1H NMR studies on six-coordinate dimethyltin bis(chelate) compounds. Chem Lett 10:273-274
52. 119Sn, 1H)| on the Me-Sn-Me angle in methyltin(IV) compounds. Inorg Chem 25:892-895
53. Lockhart TP (1988) Solution and solid-state structures of di-nbutyltin 3-thiopropionate. X-ray crystal structure determination of the cyclic hexamer. Organometallics 7:1438-1443
54. 119Sn Mössbauer studies on tin compounds. Blackie, London, pp 496-540
55. Greenwood NN, Gibb TC (1971) Mössbauer spectroscopy. Chapman & Hill, London
56. 119Sn Mössbauer and IR spectroscopic studies of some diorganotin(IV)carbohydrates. Polyhedron 6:383-386
57. Sham TK, Bancroft GM (1975) Tin-119 Mossbauer quadrupole splittings for distorted dimethyltin(IV) structures. Inorg Chem 14:2281-2283
58. 119Sn Mössbauer quadrupole splitting in five-co-ordinate organotin(IV) compounds. J Chem Soc, Dalton Trans 643-654
59. Szorcsik A, Nagy L, Sletten J, Szalontai G, Kamu E, Fiore T, Pellerito L, Kalman E (2004) Preparation and structural studies on dibutyltin(IV) complexes with pyridine mono- and dicarboxylic acids. J Organomet Chem 689:1145-1154
60. Szorcsik A, Nagy L, Deak A, Scopelliti M, Fekete ZA, Csaszar A, Pellerito C, Pellerito L (2004) Preparation and structural studies on the tBu2Sn(IV) complexes with aromatic mono- and dicarboxylic acids containing hetero {N} donor atom. J Organomet Chem 689:2762-2769
61. Pelizzi C, Pelizzi G, Tarasconi P (1983) Synthesis and characterization by IR spectroscopy and x-ray diffraction of a quinazolinecomplex of dibutyldichlorotin(IV). Polyhedron 2:145-147
62. IV-oxydiacetate and -iminodiacetate complexes. Inorg Chem 44:3094-3102 (Pubitemid 40758116)
63. Xueqing S, Zhiqiang Y, Qinglan X, Jinshan L (1998) Synthesis, structures and in vitro antitumor activity of some germaniumsubstituted di-n-butyltin dipropionates. J Organomet Chem 566:103-110 (Pubitemid 128338021)
64. 5 pentagonal bipyramidal dibutylbis(phenylacetato)tin(IV) hydrate. J Crystallogr Spectros Res 21:39-43
65. Dakternieks D, Kuan FS, Tiekink ERT (2001) X-ray structure of di(Acetato)-aqua-di(cyclohexyl)tin(IV). Main Group Met Chem 24:291-292 (Pubitemid 33718325)
66. Mahon MF, Molloy KC, Stanley JE, Rankin DWH, Robertson HE, Johnson BF (2005) Atmospheric pressure deposition of fluorine-doped SnO2 thin films from organotin fluorocarboxylate precursors. Appl Organomet Chem 19:658-671 (Pubitemid 40552728)
67. Molloy KC (1989) In: Hartley FR (ed) Bioorganotin compounds in the chemistry of metal carbon bond, vol 5. Wiley, New York (Chapter 11)
68. Hook JM, Linahan BM, Taylor RL, Tiekink ERT, Von Gorkom N, Webster LK (1994) Phenyltin diethyldithiocarbamates: solid state and solution structures and in vitro anti-tumour activity. Main Group Met Chem 17:293-311
69. Willem R, Dalil H, Biesemans M, Martins JC, Gielen M (1999) The reaction of di-n-butyltin oxide with hexafluoro-2, 2-bis(4- carboxyphenyl)propane. Appl Organomet Chem 13:605-608 (Pubitemid 129693183)
70. Danish M, Alt Helmut G, Badshah A, Ali S, Mazhar M, Nazar-ul- Islam (1995) Organotin esters of 3-(2-furanyl)-2-propenoic acid: their characterization and biological activity. J Organomet Chem 486:51-56